Cotinga Pharmaceuticals EBITDA
What is the EBITDA of Cotinga Pharmaceuticals?
The EBITDA of Cotinga Pharmaceuticals, Inc. is -CAD$2.14
What is the definition of EBITDA?
EBITDA is a company’s earnings before interest, taxes, depreciation, and amortization and is an accounting measure calculated using a company’s net earnings, before interest expenses, taxes, depreciation and amortization are subtracted, as a proxy for a company’s current operating profitability.
ttm (trailing twelve months)
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA of companies in the Health Care sector on TSXV compared to Cotinga Pharmaceuticals
What does Cotinga Pharmaceuticals do?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Companies with ebitda similar to Cotinga Pharmaceuticals
- One Heritage PLC has EBITDA of -£2.16
- Saturn Metals has EBITDA of -AUD$2.16
- Stratabound Minerals has EBITDA of -CAD$2.15
- Structural Monitoring Systems Plc has EBITDA of -AUD$2.15
- Felix Gold has EBITDA of -$2.15
- Aurex has EBITDA of -CAD$2.14
- Cotinga Pharmaceuticals has EBITDA of -CAD$2.14
- Pharol, SGPS S.A has EBITDA of -€2.14
- Pharol, SGPS S.A has EBITDA of -€2.14
- NTM Gold has EBITDA of -AUD$2.14
- Kintavar Exploration has EBITDA of -CAD$2.14
- Banyan Gold has EBITDA of -CAD$2.14
- Banyan Gold has EBITDA of -CAD$2.14